Search Results 891-900 of 17103 for monoclonal antibody

1. MRI Study To Identify Functional and Structural Changes That Correlate with Patient Improvement When Imaging the Brain Pre-and-Post Erenumab - Mayo Clinic

   Has received CGRP monoclonal antibody within 4 months of the start of the run‐in phase. Active chronic pain condition that in the investigator's opinion is ...

2. Overview - Mayo Clinic

   Monoclonal gammopathy-associated conditions including C1-esterase inhibitor deficiency, cryoglobulinemia, osteosclerotic myeloma, peripheral neuropathy ...

3. Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary - Mayo Clinic

   ... monoclonal antibody or hypersensitivity to pembrolizumab or any of its excipients. Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks ...

4. A Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab with or without Chemotherapy or Lenvatinib (E7080/MK 7902) in Subjects with Advanced Solid Tumors - Mayo Clinic

   Subjects enrolled in the PD-1-treatment-failure HNSCC cohort must be refractory to an FDA approved anti-PD-1/PD-L1 monoclonal antibody ... antibodies), or ...

5. Hematology - Clinical trials

   The purpose of this study is to determine the cellular and mechanistic basis of bone marrow hematopoietic dysfunction in untreated Monoclonal B Cell ...

6. A Study to Evaluate CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma - Mayo Clinic

   ... antibody. Eastern Cooperative Oncology Group (ECOG) performance status ... monoclonal antibodies ≤ 14 days prior to registration. Patients who have ...

7. ASCENT-Study of Sacituzumab Govitecan in Refractory/Relapsed Triple-Negative Breast Cancer - Mayo Clinic

   Prior antibody treatment for cancer must have been ... Sacituzumab govitecan-hziy is an antibody-drug conjugate that combines a humanized monoclonal ...

8. BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study - Mayo Clinic

   to fistula formation. - Participants must not have received investigational agents or monoclonal antibodies (except Food and Drug Administration [FDA] ...

9. Seroprevalence Study of Pre-existing Immunity for Adenovirus-associated Virus Vector in MYBPC3-associated Hypertrophic Cardiomyopathy - Mayo Clinic

   Currently receiving systemic immunosuppressive therapy, cytotoxic chemotherapy, immunoglobulin therapy, or monoclonal antibody therapy. History of ...

10. A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Effectiveness of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma - Mayo Clinic

    History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products.